

Fax completed form to: 1-866-868-0858

Questions, please call: 1-866-316-6049

**TODAY'S OPTIONS®**

**Important Information About Prescription Drug Coverage**

---

To: \_\_\_\_\_ From: \_\_\_\_\_

Fax: \_\_\_\_\_ Pages: \_\_\_\_\_

Re: Remicade® (infliximab): Prior Authorization Request Form: Please respond.

---

- Please complete the attached Remicade® (infliximab) Prior Authorization Request Form
- To expedite the review process please complete all requested fields.
- Completed forms should be faxed to: 1-866-868-0858. It is not necessary to fax this cover page.

**Please note:** By signing the attached form you are certifying that the treatment requested is medically necessary. No contraindications are present and precautions have been considered. You will be supervising the patient's treatment. Supporting documentation is available in the patient's record. Signature on this form attests to the fact that the corresponding ICD-9 code has been documented in the patients chart and submitted on a CMS- 1500 form.

**Information about this drug**

---

**Remicade® (infliximab)**

Increased rates of malignancy, hepatic dysfunction, exacerbation of HF and demyelinating disease have been reported in Remicade® treated patients. Please consider alternative DMARDs if appropriate. Hepatotoxicity and reactivation of hepatitis B virus in chronic carriers has been reported. Evaluate patients for risk of Hepatitis B and latent tuberculosis prior to therapy initiation.

You can make an expedited request by indicating this at the top of the attached form. If you request an expedited review, and sign the attached form, you certify that applying the 72 hour standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

**Information on the attached form is protected health information and subject to all privacy and security regulations under HIPAA.**

# Prior Authorization Request Form

Fax completed form to 1-866-868-0858 Need help? Call 1-866-316-6049

## Patient Information

Name \_\_\_\_\_  
Member ID \_\_\_\_\_  
Medicare ID \_\_\_\_\_  
Date of birth \_\_\_\_\_ Sex: M / F  
Address \_\_\_\_\_  
City \_\_\_\_\_  
State \_\_\_\_\_ ZIP \_\_\_\_\_  
Phone \_\_\_\_\_  
Nursing home resident? YES / NO  
Home care patient? YES / NO

## Prescriber and Pharmacy Information

Name \_\_\_\_\_  
Specialty \_\_\_\_\_  
DEA \_\_\_\_\_  
NPI \_\_\_\_\_  
Address \_\_\_\_\_  
City \_\_\_\_\_  
State \_\_\_\_\_ ZIP \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_  
Pharmacy name \_\_\_\_\_  
NCPDP \_\_\_\_\_  
NPI \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_

## All items below this line are for Physician Use Only

### Information for Requested Drug

Strength: \_\_\_\_\_ Dosage form: \_\_\_\_\_ Qty per 30 days: \_\_\_\_\_ Drug is (circle one): Newly prescribed/Refill  
Directions: \_\_\_\_\_ Diagnosis: \_\_\_\_\_ ICD-9 Code: \_\_\_\_\_

Standard Reviews will be completed in under 72 hours. An expedited review is available if you certify that a standard review timeframe will seriously jeopardize the health of your patient. To request an expedited review, simply indicate this at the top of this page.

### Remicade® (infliximab) Criteria

- Please indicate dispensing location:  
 the pharmacy  
 the physician's supply incident to a physician's service  
 other: \_\_\_\_\_
- Please indicate the patient's diagnosis. Select or specify the correct ICD-9 code. This question must be completed  
 Moderate to Severe Crohn's Disease (ICD-9:555)  
 Severe Crohn's disease in a pediatric patient (ICD-9:555)  
 Rheumatoid Arthritis (ICD-9:714)  
 Ankylosing Spondylitis (ICD-9:720)  
 Fistulizing Crohn's Disease (ICD-9: 569.81, 565.1)  
 Ulcerative Colitis (ICD-9:555, 556)  
 Psoriasis with arthropathy (ICD-9:696)  
 Other (diagnosis and ICD-9) \_\_\_\_\_
- Is the prescribing physician a rheumatologist, dermatologist or gastroenterologist or has one been consulted?  
 Yes  No
- Does the patient meet any of the following exclusion criteria? (check all that apply)  
 Yes  No
  - Active infection (e.g., chronic leg ulcers, recurrent respiratory infections, indwelling catheter, TB, hepatitis B/C, HIV)
- Has patient failed to receive a clinically appropriate therapeutic response OR demonstrated intolerance (e.g., allergy, hypersensitivity, adverse effects, development of a contraindication) for a period of 30 or more days for each drug as indicated below. Please check applicable diagnosis:  
 Yes  No
  - Ulcerative Colitis At least 2 of the following have been tried: Glucocorticoids, mesalamine, sulfasalazine, olsalazine, balsalazide.
  - Rheumatoid arthritis/ ankylosing spondylitis/ Crohn's Disease/ psoriatic arthropathy: The biological agent Humira® has been tried.
  - Plaque psoriasis at least one systemic DMARD medication (e.g., acitretin, methotrexate, cyclosporine) AND at least one topical antipsoriasis medication (e.g., corticosteroid, Dovonex®, Tazorac®, anthralin) over a period of 30 or more days for each drug.

Medical justification: (Attach additional page if necessary): \_\_\_\_\_

Prescriber's signature: \_\_\_\_\_ Date: \_\_\_\_\_